Japan’s Pharma industry

japanstrategy.com

Japan’s pharma markets overview

Japan’s pharmaceutical market is the third largest globally:

  • USA: US$ 425 billion (2020)
  • Europa: US$ 200 billion (2020)
  • Japan: US$ 150 billion (2020)

Japan’s pharma industry includes many different segments from

  • traditional pharma companies (including the 15 largest are listed below),
  • new entrants (eg brewery companies, electrical conglomerates, chemical conglomerates, rubber companies…. entering the life science sector)
  • pharma manufacturing, contract cell manufacturers (eg FujiFilm)
  • ventures (eg cell therapy, regenerative medicine sectors)
  • medical equipment (eg Olympus)
  • and other sectors

For our business development and M&A work we are continuously developing a large proprietary data base of Japan’s pharmaceutical industry, medical equipment, and related industries, research institutions, ventures, venture funds, and industry associations.

Our platform includes on the order of

  • 110 Japanese pharmaceutical companies (far beyond the top 15 listed below, and including a long tail of small and mid-sized pharma companies and ventures),
  • 230 Japanese companies in the regenerative medicine, cell therapy sector
  • data base of pharma organizations, research centers, research parks, venture funds, research organizations and more

Japan’s top 15 pharma groups

Ranking depends on criteria and varies year by year:

  1. Chugai (Hoffmann-La Roche holds 61.16% of shares excluding treasury stock, 59.89% of outstanding shares) sales US$ 5.2 billion (2022)
  2. Takeda US$ 5 billion
  3. Eisai US$ 4 billion
  4. Astellas US$ 3.8 billion
  5. Otsuka Holdings US$ 3.6 billion
  6. Daiichi Sankyo US$ 3.2 billion
  7. Mitsubishi Tanabe Pharma (absorbed by Mitsubishi Chemical) US$ 2.7 billion
  8. Sawai Pharmaceutical US$ 2 billion
  9. Kyowa Hakko Kirin US$ 1.8 billion
  10. Shionogi US$ 1.6 billion
  11. Santen Pharma US$ 1.5 billion
  12. Ono Pharma US$ 1.3 billion
  13. Nippon Shinyaku US$ 1.2 billion
  14. Sumitomo Pharma (was Sumitomo Dainippon Pharma) US$ 1.1 billion
  15. Mochida Pharma US$ 1 billion

(c) 2024 Eurotechnology Japan KK All rights reserved.